Theorem Implements SAS Clinical Data Integration to Save Sponsors Time and Resources and Ensure Quality - Applied Clinical Trials

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
Theorem Implements SAS Clinical Data Integration to Save Sponsors Time and Resources and Ensure Quality

Source: Company News Release
Theorem Clinical Research continues to broaden its ability to help sponsors optimize trial conduct, recently implementing SAS® Clinical Data Integration (SAS CDI), an innovative solution that automates the process of transforming, managing and verifying the creation of industry-mandated data standards.

SAS enables Theorem to automate the mapping of standard electronic data capture (EDC) databases and external data into standard data sets that are compliant with the Clinical Data Interchange Standards Consortium (CDISC). By using the technology for routine tasks, Theorem can now more easily manage standards throughout the entire life cycle.

Additionally, SAS CDI will be leveraged to automate Theorem’s clinical data warehouse and highly visual data discovery tools, reducing time and effort to obtain clinical data in real time.

“As an early supporter of CDISC, Theorem recognized the value that standardization and harmonization would bring to clinical data and reporting,” said Mark Penniston, executive vice president of clinical analytics for Theorem. “Now we’re able to combine our deep experience in developing CDISC-compliant data domains with SAS technology to produce high-quality, standardized data sets faster and more efficiently.”

Kecia Serwin, vice president, SAS Health Care and Life Sciences, commented, “We’re delighted that Theorem has joined the list of leading life science organizations who’ve chosen SAS to streamline standards adoption in drug development processes.”

As a CDISC Registered Solutions Provider, Theorem was among the first global contract research organizations to execute a CDISC-compliant submission in 2004 and has created more than 50,000 CDISC-compliant data sets to date.

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
86%
Borrow lightly from EMA's pathway program?
6%
Create entirely its own pathway program?
7%
View Results
Untitled Document
Source: Company News Release,
Click here